CancerDrs

Cervical Cancer clinical trials in Alabama

13 actively recruiting cervical cancer trials at 4 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Alabama:
  • Site 160 — Mobile, Alabama
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Alabama:
  • Children's Hospital of Alabama — Birmingham, Alabama
Phase 2 Recruiting Academic/Other

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.

Sponsor: University of Alabama at Birmingham
NCT ID: NCT04511078
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05208762
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of Alabama at Birmingham, IDS Pharmacy — Birmingham, Alabama
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Industry

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for part…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT07219212
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
Phase 1 Recruiting Academic/Other

Study of Treatment for HPV16+ ASC-US or LSIL

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

Sponsor: University of Alabama at Birmingham
NCT ID: NCT03913117
Sites in Alabama:
  • UAB | The University of Alabama at Birmingham — Birmingham, Alabama
EARLY Phase 1 Recruiting Academic/Other

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standar…

Sponsor: University of Alabama at Birmingham
NCT ID: NCT05183048
Sites in Alabama:
  • UAB — Birmingham, Alabama
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama:
  • Massive Bio SYNERGY-AI site — Birmingham, Alabama
  • Massive Bio SYNERGY-AI site — Mobile, Alabama
NA Recruiting Academic/Other

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Alabama:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • University of South Alabama — Mobile, Alabama
NA Recruiting Industry

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with th…

Sponsor: Varian, a Siemens Healthineers Company
NCT ID: NCT05197881
Sites in Alabama:
  • University of Alabama Birmingham — Burmingham, Alabama
NA Recruiting Academic/Other

Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama

The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.

Sponsor: University of Alabama at Birmingham
NCT ID: NCT04093388
Sites in Alabama:
  • Cahaba Medical Care - West End — Birmingham, Alabama
  • Cahaba Medical Care - Ensley — Birmingham, Alabama
  • Cahaba Medical Care — Centreville, Alabama

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15